A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
At a glance
- Drugs SGM 1019 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Second Genome
- 05 Feb 2019 Planned End Date changed from 1 Nov 2019 to 1 Dec 2019.
- 23 Jan 2019 Status changed from not yet recruiting to recruiting, according to a Second Genome media release.
- 23 Jan 2019 According to a Second Genome media release, Stephen Harrison, Medical Director of Pinnacle Clinical Research, is the Principal Investigator of this study.